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13.01.003Abstract DNA sequencing using reversible terminators, as one sequencing by synthesis strategy,
has garnered a great deal of interest due to its popular application in the second-generation
high-throughput DNA sequencing technology. In this review, we provided its history of develop-
ment, classiﬁcation, and working mechanism of this technology. We also outlined the screening
strategies for DNA polymerases to accommodate the reversible terminators as substrates during
polymerization; particularly, we introduced the ‘‘REAP’’ method developed by us. At the end of
this review, we discussed current limitations of this approach and provided potential solutions to
extend its application.Introduction
Dideoxy sequencing method, developed by Frederick Sanger
et al. in 1977, contributed substantially to development of
biological sciences in the past several decades [1]. As the core
technology, it brought the great successful completion of the
Human Genome Project (HGP) [2]. However, high cost and
low throughput inherited within the method had limited its
application to meet the ever-expanding appetite for large scale
genome sequencing projects, including de novo sequencing of
more species, whole-genome resequencing, and deep sequenc-
ing. Therefore, the second-generation sequencing technology,.
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ing Institute of Genomics, Chinese Accharacterized by its high speed, high throughput, and lower
cost, appeared on the scene [3–5].
Since 2005, the second-generation sequencing technologies
have experienced a rapid development: different sequencing
platforms came to market and data produced by these new
technologies mushroomed exponentially. These achievements
not only provided large amount of raw data for scientiﬁc re-
search, but also uncovered new scientiﬁc ideas, and revolution-
arily changed our ways of working in life sciences [3–7]. Now,
the third-generation sequencers, represented by single molecule
real-time sequencer (SMAT) from PacBio [8], are also on the
horizon. But due to the relatively high single read error rate
(15%) [9], the second-generation sequencing technologies
are still the mainstream in whole-genome sequencing markets.
So far, technologies employed in the second-generation
sequencing platforms are of two main types based on sequenc-
ing chemistry: ‘‘sequencing by synthesis’’ and ‘‘sequencing by
ligation’’ [10,11]. Reversible termination sequencing is one of
the sequencing-by-synthesis strategies popularized by Illu-
mina/Solexa due to its wide adoption in the worldwide sec-ademy of Sciences and Genetics Society of China. Published by Elsevier Ltd
Figure 1 Structure schematic of irreversible and reversible termi-
nators used in sequencing technologies
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share) [12]. In the following sections, we give a brief introduc-
tion on the developmental history and current status of this
technology, discuss the limitations, and suggest potential solu-
tions of its uses in detail.
The history and classiﬁcation of reversible
termination sequencing technology
Reversible termination sequencing technology was ﬁrst re-
ported by Dr. Jingyue Ju from Colombia University [13].
The prime difference between this approach and the traditional
Sanger sequencing method is that the former uses modiﬁed
nucleotide analogous to terminate primer extension reversibly,
while the latter employs dideoxynucleotide to irreversibly ter-
minate primer extension (Figure 1) [5].
With the development over the last decade, several reversible
terminatorswere produced. They can be classiﬁed into two types
based on the difference of the reversible blocking groups [11–23].
One type is 30-O-blocked reversible terminators. As shown in
Figure 1B, the blocking group –OR [reversible terminatingTable 1 Comparison of four main second-generation sequencing plat
Feature Roche/454 Ion-t
Read size (bp) 500–1000 200
Throughput 700 Mb 1 Gb
Time required/run 23 h 2 h
Coverage/dpl h-genome 10· 20·
Run/dpl h-genome 43 60
Days/h-genome 43 5
Cost ($USD)/run 7000 4000
Cost ($USD)/h-genome 300,000 240,0
Note: dpl stands for diploid.(capping) group] is linked to the oxygen atom of the 30-
OH of the pentose, while the ﬂorescence label is linked to
the base, which acts as a reporter and can be cleaved [12–
18]. The other type is 30-unblocked reversible terminators
[19–23] as shown in Figure 1C. In this case, the reversible
termination group is linked to the base as well as the ﬂores-
cence group which not only is a reporter but also functions
as part of the reversible terminating group for termination
of the primer extension. These two types of reversible termi-
nators have their advantages and disadvantages: the 30-O-
blocked reversible terminator contains a 30 reversible block-
ing group, thus should render better termination effect; the
30-unblocked reversible terminator, on the other hand, is eas-
ier to be accepted by the DNA polymerases due to the lack
of a modiﬁed moiety at the 30-OH. Because polymerases
have evolved for billions of years to discriminate between
ribonucleoside triphosphates and 20-deoxyribonucleoside tri-
phosphates, they have evolved to inspect the 20- and 30-posi-
tions of their substrates closely. For example, although the
only difference between dideoxyribonucleoside and deoxyri-
bonucleoside is the presence or absence of oxygen atom at
the 30 position, accepting a dideoxyribonucleoside for all
known DNA polymerases will prevent further catalytic elon-
gation of additional nucleoside afterward [17,24].
For the ﬁrst type, there are three commercially-available
reversible terminators with a blocking group at 30-OH
(structures shown in Figure 2A–C): the 30-ONH2 reversible
terminator developed by Dr. Steven A. Benner and his col-
leagues from Foundation for Applied Molecular Evolution
(FfAME) [17,18]; the 30-O-allyl reversible terminator created
by Jingyue Ju and his colleagues from Colombia University
[5]; the 30-O-azidomethy reversible terminator developed and
used by Illumina Solexa [12]. All three commercial reversible
terminators were reported to show good performance in
reversible termination function: achieving nearly 100% of
30-O blocking efﬁciency and ﬂorescent label group cleavage
after primer extension termination [12–18].
For the second type, hitherto, there is only one commercial
30-OH unblocked reversible terminator named ‘‘virtual termi-
nator’’, which is developed by Helicos BioSciences Corpora-
tion (Figure 2D) and employed by the ﬁrst ‘‘single molecule’’
sequencer to hit the market in the emerging third generation
of DNA sequencing platform [19]. In addition, the ‘‘Lightning
terminator’’ recently developed by Michael L. Metzker’s group
also belongs to 30-OH unblocked reversible terminator (the
lower panel in Figure 2E), and is unique in using UV light to
cleave the ﬂuorescent group [20–23].forms
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Figure 2 Several commercial reversible terminators
Three different 30-blocked reversible terminators were shown on the left (A–C) and two 30-unblocked reversible terminators were shown on
the right (D–E). The chemical structures in red denote the reversible terminating groups. Arrows indicate the site of cleavage separating
the ﬂuorescent groups from the nucleotide, and the chemical structures in blue denote the molecular scars that are attached to the base.
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sequencing technology
Reversible termination sequencing technology is a sequencing-
by-synthesis approach [3–5] that infers the sequence of a tem-
plate by stepwise primer elongation. It is popularized as a sec-
ond generation sequencing technology on the Illumina
platform. The general reversible termination sequencing pro-
cess involves (i) immobilizing the sequencing templates and
primers on a solid support; (ii) primer extension by one base
and termination; (iii) recognizing the color of the ﬂuorophore
carried by the extended base to identify the incorporated
nucleotide after washing away the unincorporated nucleotides;
(iv) removal of the ﬂuorescent tag and the 30-O blocking group;
(v) washing again and repeating the aforementioned steps (ii–
iv). The whole process can be summarized as extension–termi-
nation–cleavage–extension cycle (Figure 3).Screening proper polymerases for their abilities to
accept the reversible terminators
After design and synthesis of a reversible terminator, ﬁrst we
need to ﬁnd a proper polymerase to accept the nucleotide ana-
log. Due to the speciﬁcity of enzyme and the special structures
of the reversible terminating nucleotides, it is difﬁcult to get a
proper polymerase to accept them with high efﬁciency and
ﬁdelity. Proper polymerases were usually obtained after exper-imenting potential candidates through primer extension
screenings [17,18] (Figure 4).
Based on screening libraries, two approaches are applied to
select the proper polymerases for the reversible terminators
[17,18]. One simple approach is to screen the polymerases from
commercially-available DNA polymerases and reverse tran-
scriptases [18]. If no desired polymerase can be obtained in this
screening, another approach can be taken to obtain the proper
polymerases from mutation libraries constructed through ra-
tional design, ‘‘directed evolution’’ (random mutation), or
semi-rational design (combination of rational design with di-
rected evolution) [17].
Many commercially-available DNA polymerases, such as
Therminator, Klenow, Bst and 9Nm DNA polymerases, have
been reported to work well with the reversible terminating
nucleotides [12,15,18,20]. Jingyue Ju’s group used AmpliTaq
DNA polymerase in their sequencing process (Invitrogen)
due to its good compatibility to a large ﬂuorescent group at
50 position of pyrimidine and 70 position of purine [15]. A mu-
tant 9Nm DNA polymerase was adopted by Illumina Solexa,
but the mutation sites are unknown due to commercial consid-
eration [12]. For the same reason, Helicos did not disclose the
DNA polymerase used in their sequencing platform [19].
‘‘Lightning terminator’’ research group screened eight com-
mercial DNA polymerases, among which Bst DNA polymer-
ase demonstrated the best incorporation efﬁciency for the
‘‘Lightning terminator’’ [20]. In addition, Steven A. Benner
et al. found that some reverse transcriptases showed unex-
pected compatibility for nucleotide analogs [24].
Figure 3 Schematic showing sequencing during synthesis using 30-
O blocking reversible terminators
Each triphosphate has its 30-OH group blocked and a ﬂuorescent
tag attached to its nucleobase via a cleavable linker. The blue
arrow indicates the residual linker ‘‘scar’’ after cleavage of
ﬂuorescent group.
Figure 4 Screening the proper polymerases compatible with the revers
c 32P-labeled primer was ﬁrst annealed with the template, followed by t
initiated by adding the candidate polymerases, and evaluated by runn
Figure 5 An evolutionary tree describing the amino acid at a single
site in a protein family
The capital letters represent different amino acid residues. Such a
‘‘conserved but different’’ site in a protein family is a target for
protein engineering.
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lutionary adaptive path (REAP), developed by us, was
proved to be a useful tool to genetically engineer the poly-
merases to accept the reversible terminator [17]. This strategy
is based on the concept of ‘‘conserved but different’’ pattern,
introduced by Steven A. Benner et al. more than two decades
ago [25,26]. Figure 5 illustrates this concept. Here, sites are
identiﬁed where the residue has not been absolutely con-
served in all proteins in the family, but rather conserved with-
in sub-branches of the family. The fact that the residue is
conserved in sub-branches of the family means that it is un-
der relatively strong functional constraints, implying its
importance for some aspects of enzymatic function. This, in
turn, infers that behavior of the polymerase is likely to
change if the residue at the site is modiﬁed. The fact the res-
idue is not absolutely conserved, however, means that the siteible terminators using primer extension method
he addition of the reversible terminator. Primer extension was then
ing the samples on denaturing PAGE gel.
Table 2 Comparison of several commercial reversible terminators
Terminator Reads size (bp) Sequencing platforms Ref
30-O-N3 reversible terminator 100–150 Illumina/Solexa [12]
30-ONH2 reversible terminator 40–50 Polonator/Intelligent bio-systems [17]
30-O-allyl reversible terminator 40–50 Intelligent bio-systems [5]
Virtual terminator 30 Hilicos [19]
Figure 6 The accumulation of scars in Illumina/Solexa sequencing
Schematic shows that two Illumina/Solexa reversible terminators (to cleave the ﬂuorescent group and 30 blocking group from the
nucleotides) are added to the 30-end of a primer in a template-directed extension reaction. The chemical structures in blue denote the
molecular scars left behind.
38 Genomics Proteomics Bioinformatics 11 (2013) 34–40can tolerate some degree of variations without destroying the
core functionality of the protein, such as folding or catalytic
activity. Therefore, such ‘‘conserved but different’’ sites are
preferred targets for protein engineering in our REAP meth-
od. Several of the variant Taq polymerases that accept 30-
ONH2 reversible terminator have emerged through the appli-
cation of this strategy [17].The opportunity and challenge of reversible
termination sequencing technologyThe great success of Human Genome Project signiﬁcantly
energized the development of more cost-effective sequencing
technology [2]. Especially since 2005, the development and
Chen F et al / Reversible Terminators Used in Gene Sequencing 39application of next generation sequencing (NGS) technology,
characterized by its low cost and high throughput through
massively parallel sequencing, displays an unprecedented tech-
nological breakthrough in biology, medicine and many related
ﬁelds. Due to various advantages, reversible termination
sequencing technology has been widely accepted and used in
multiple NGS platforms, including the most successful NGS,
Illumina/Seloxa sequencer and the ﬁrst third-generation single
molecule sequencer, Helicos sequencer [3,4,12,19]. This
technology uses ﬂuorescent labels as sequencing reporter,
which not only affords great sensitivity and sequencing accu-
racy but also markedly decreases the amount of sample re-
quired. In addition, the application of reversible termination
strategy effectively solves the problem of accurate identifying
homopolymeric runs (such as PolyA) which are difﬁcult to
achieve using pyrosequencing technology. It was reported that
the reversible termination sequencing could accurately read
out more than 18 consecutive A [26,27].
Although ‘‘sequencing using cyclic reversible terminator’’
brings about new opportunities to the development of sequenc-
ing techniques, some problems still exists, among which, short
read length has always been a major weakness. As the most
popular NGS platform, the read length of the Illumina/Solexa
sequencing platform is only around 100–150 bp (Tables 1 and
2). Drawbacks of short read length in shot-gun sequencing,
especially de novo, are obvious.
One of the fundamental reasons for short read length in
‘‘sequencing using cyclic reversible terminator’’ is that revers-
ible terminator nucleotide analogs developed so far leave be-
hind a vestige (‘‘scar’’) after cleavage of the linker carrying
the ﬂuorophore. Figure 6 illustrates the accumulation of such
scars along the major groove of the DNA duplex after two
rounds of sequencing extension on Illumina/Solexa platform.
Accompanied by primer extension, such accumulation of scars
snowballed, impairing the stability of DNA double-helix struc-
ture adversely and, thus, hindering substrate recognization and
primer extension. Through adding a certain proportion of
reversible terminator nucleotide analogs without the ﬂuoro-
phore, some base incorporations (e.g., Illumina/Solexa) leave
no vestige, alleviating the impact of scars accumulation to a
certain extent and extending read length. However, in order
to overcome this deﬁciency thoroughly, new solutions are still
a matter with great urgency. Recently, Metzker and colleagues
made some advancement in this respect [20–23]. In their sys-
tem, the scar left after cleavage of the linker is very small (Fig-
ure 2E), suggesting a potential to completely or at least
partially overcome the drawback of short read length in
‘‘sequencing using cyclic reversible terminator’’.
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